Loading company…
Oxurion develops treatments for retinal vascular disorders and other diseases affecting the back of the eye.
Oxurion NV and ThromboGenics Inc. develop ophthalmic therapies for diseases affecting the back of the eye, including diabetic macular edema, wet age-related macular degeneration and retinal vein occlusion. The company also offers JETREA® (ocriplasmin) for symptomatic vitreomacular adhesion and traction. Based in Leuven, Belgium, Oxurion is listed on Euronext Brussels under OXUR and employs 56 people worldwide.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in